United States - English - NLM (National Library of Medicine)

stat rx usa llc - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine hydrochloride 10 mg - strattera is indicated for the treatment of attention–deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)]. a diagnosis of adhd (dsm–iv) implies the presence of hyperactive–impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate diagnosis re

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 100 mg) - capsule, hard - excipient ingredients: iron oxide red; gelatin; iron oxide yellow; dimeticone 350; sodium lauryl sulfate; pregelatinised maize starch; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 91.42 mg (equivalent: atomoxetine, qty 80 mg) - capsule, hard - excipient ingredients: iron oxide red; sodium lauryl sulfate; gelatin; iron oxide yellow; titanium dioxide; dimeticone 350; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 68.56 mg (equivalent: atomoxetine, qty 60 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; indigo carmine; titanium dioxide; dimeticone 350; iron oxide yellow; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 45.71 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: sodium lauryl sulfate; indigo carmine; titanium dioxide; gelatin; pregelatinised maize starch; dimeticone 350; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 28.57 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; dimeticone 350; gelatin; indigo carmine; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 20.57 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; sodium lauryl sulfate; dimeticone 350; titanium dioxide; iron oxide yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 11.43 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; gelatin; sodium lauryl sulfate; dimeticone 350; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

United States - English - NLM (National Library of Medicine)

eli lilly and company - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)] . a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate diagnosis r

United States - English - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 25 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of